May 13th 2024
With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued education and course-setting for all stakeholders in charting the access landscape is paramount.
Can Global Innovation in Oncology be Sustained in the Face of Price Controls?
November 21st 2019Pricing in the context of patient access and affordability continues to present problems and constitute a real threat to innovation. Meaningful reform involves rectifying market imperfections in public and private third-party prescription drug payment sectors, writes Robert A. Freeman.
Managing the 3 Fronts of the Drug Pricing Conundrum: Policy, Creativity, Collaboration
August 27th 2019The impacts of disruptive curative therapies and advances in the future of health will be profound. To be best positioned for success, healthcare systems under continuous cost pressure must address three key areas, writes Thomas Unger.
Outcomes-Based Contracting: The Next Step to Better Patient Care
July 1st 2019While there are challenges at every turn, the promise of outcomes-based contracting is a level of care for patients that might otherwise not be possible, while striking the right balance of benefits and risks for all parties involved, writes Melonie Warfel.